MAPK3 and neoplasm: As shown in Fig 5D, pretreatment of all three tumor cells (MCF7, PC3, or M628) with the ERK1/2 pharmacological inhibitor (U0126) significantly blocked the Poly-G3-mediated reversal of tumor-induced T-cell senescence.